Divalproex Sodium
Product Images NDC 70518-3459

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-3459). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Divalproex Sodium 250mg 70518 3459 01)

Divalproex Sodium 250 mg delayed-release tablet label by RemedyRepack Inc. It shows quantity of 1 tablet and includes usage instructions not to crush or chew the tablet. The manufacturer is Upsher-Smith Labs, Inc., Minneapolis, MN. The label includes barcode, NDC 70518-3459-01, and repackaging details from Indiana, PA.*

FDA Label Image

Remedy_label (Remedy Label)

Label for Divalproex Sodium 250 mg delayed-release tablets. The box contains 100 tablets. The label includes directions to swallow whole without crushing or chewing and notes valproic acid activity. The product is repackaged by RemedyRepack Inc., with the original manufacturer listed as Upsher-Smith Labs, Inc.*

FDA Label Image

Chemical Structure (Divalproex 01)

Chemical structure of Divalproex Sodium illustrating its molecular components including sodium ion and associated hydrocarbon chains.*

FDA Label Image

Figure 1 (Divalproex 02)

A bar chart comparing percentages for placebo (PBO) and Divalproex Sodium (DVPX) in two studies. Study 1 uses YMRS, showing 26% for PBO and 60% for DVPX. Study 2 uses MRS, showing 29% for PBO and 58% for DVPX. Percentages are on the vertical axis from 0% to 70%.*

FDA Label Image

Figure 2 (Divalproex 03)

A line graph comparing the percentage reduction in clinical parameter scale (CPS) rate between Divalproex sodium and placebo across different percentages of patients. The vertical axis shows the percentage reduction in CPS rate from -100% to 100%, with labels indicating worsening, no change, and improvement. The horizontal axis represents the percentage of patients from 0 to 100%. Two lines are shown: a solid line for Divalproex sodium and a dashed line for placebo, indicating differing response distributions between the treatments.*

FDA Label Image

Figure 3 (Divalproex 04)

A line graph showing percentage reduction in CPS (complex partial seizure) rate on the y-axis versus percentage of patients on the x-axis. Two dose groups are compared: High Dose (solid line) and Low Dose (dashed line). The graph also includes directional indicators for Improvement (upward) and Worsening (downward) in CPS rate.*

FDA Label Image

Figure 4 (Divalproex 05)

A bar chart comparing values between Placebo and Divalproex Sodium groups across two studies labeled Study 1 and Study 2. The vertical axis ranges from 0 to 6, showing that in both studies, Placebo bars are higher than Divalproex Sodium bars, indicating a comparison of measured outcomes between treatments.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.